LSV Asset Management Buys 184,026 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

LSV Asset Management boosted its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 23.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 956,217 shares of the company's stock after buying an additional 184,026 shares during the quarter. LSV Asset Management owned approximately 1.68% of Harmony Biosciences worth $32,903,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the stock. Vanguard Group Inc. raised its stake in shares of Harmony Biosciences by 36.4% in the fourth quarter. Vanguard Group Inc. now owns 4,733,609 shares of the company's stock valued at $162,883,000 after acquiring an additional 1,262,362 shares during the last quarter. Norges Bank bought a new stake in shares of Harmony Biosciences during the fourth quarter worth $16,118,000. Pacer Advisors Inc. increased its stake in shares of Harmony Biosciences by 18.2% in the fourth quarter. Pacer Advisors Inc. now owns 2,279,918 shares of the company's stock valued at $78,452,000 after buying an additional 351,582 shares in the last quarter. Invesco Ltd. raised its holdings in shares of Harmony Biosciences by 173.9% in the fourth quarter. Invesco Ltd. now owns 449,180 shares of the company's stock valued at $15,456,000 after buying an additional 285,156 shares during the last quarter. Finally, American Century Companies Inc. lifted its position in Harmony Biosciences by 28.7% during the 4th quarter. American Century Companies Inc. now owns 1,102,604 shares of the company's stock worth $37,941,000 after buying an additional 246,140 shares in the last quarter. 86.23% of the stock is currently owned by institutional investors.

Harmony Biosciences Trading Up 0.9 %

Harmony Biosciences stock traded up $0.25 during mid-day trading on Thursday, hitting $28.19. 168,948 shares of the company's stock were exchanged, compared to its average volume of 676,674. Harmony Biosciences Holdings, Inc. has a fifty-two week low of $26.47 and a fifty-two week high of $41.61. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28. The firm has a market capitalization of $1.62 billion, a P/E ratio of 13.36, a PEG ratio of 0.47 and a beta of 0.80. The company's 50 day simple moving average is $33.30 and its 200-day simple moving average is $34.61.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported $0.85 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.11. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The business had revenue of $201.30 million for the quarter, compared to analysts' expectations of $201.25 million. During the same quarter in the previous year, the business posted $0.45 EPS. Harmony Biosciences's revenue for the quarter was up 19.5% on a year-over-year basis. On average, equities analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Insider Activity

In related news, CFO Sandip Kapadia sold 1,775 shares of the stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $38.05, for a total transaction of $67,538.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jeffrey Dierks sold 1,629 shares of the business's stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $38.02, for a total value of $61,934.58. The disclosure for this sale can be found here. Insiders sold 61,945 shares of company stock worth $2,442,815 over the last quarter. 30.80% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

HRMY has been the subject of a number of research analyst reports. Mizuho boosted their target price on shares of Harmony Biosciences from $42.00 to $44.00 and gave the stock an "outperform" rating in a research note on Tuesday, March 18th. HC Wainwright reaffirmed a "buy" rating and set a $70.00 price objective on shares of Harmony Biosciences in a report on Tuesday, April 8th. Needham & Company LLC reissued a "buy" rating and issued a $50.00 target price on shares of Harmony Biosciences in a research note on Tuesday, April 8th. Finally, Deutsche Bank Aktiengesellschaft began coverage on Harmony Biosciences in a research report on Tuesday, February 11th. They set a "buy" rating and a $55.00 target price for the company. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $53.33.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.